or Try an Advanced Search...

    Castration Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    AMGN B Amgen Inc. 0.37
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major
    Related Stock Lists: Biotechnology Blood Cells Bone Bone Disease Cancer Care Clinic Dialysis Dow Jones Component Drugs Epidermal Growth Factor Receptor Growth Factors Healthcare Providers Hematology Human Therapeutic Products Inflammation Inflammatory Diseases Medicine Metastases Mimics Monoclonal Antibody

    Related ETFs - A few ETFs which own one or more of the above listed Castration Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    BBH C Market Vectors Biotech ETF 15.08
    IBBQ C Invesco Nasdaq Biotechnology ETF 8.69
    IBB C iShares Nasdaq Biotechnology Index Fund 8.68
    BIS C ProShares UltraShort Nasdaq Biotechnology 8.14
    BIB C ProShares Ultra Nasdaq Biotechnology 6.29
    View all Castration Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare BBH to BIS Compare BBH to IBB Compare IBB to BIS

        Castration Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        May 3 AMGN Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
        May 3 AMGN Apple, Coinbase, Block, Amgen, Tesla: Why These 5 Stocks Are On Investors' Radars Today
        May 2 AMGN Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
        May 2 AMGN Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections Amid Revenue Growth and Challenges
        May 2 AMGN Amgen stock rallies 13% amid weight-loss drug updates, tweaked guidance
        May 2 AMGN Amgen Soars After CEO Gives Update on Experimental Obesity Drug
        May 2 AMGN Amgen, DraftKings, Live Nation: Trending tickers
        May 2 AMGN UPDATE 1-Amgen first-quarter profit dips 1%, revenue rises 22%
        May 2 AMGN Amgen Surges On Strong First-Quarter Profit As Obesity Space Heats Up
        May 2 AMGN Amgen in charts: Major drug sales grow at slower pace Y/Y, rev from Enbrel dips in Q1
        May 2 AMGN Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line
        May 2 AMGN Amgen 'encouraged' by weight-loss drug interim data, shares jump
        May 2 AMGN AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
        May 2 AMGN Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
        May 1 AMGN Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
        May 1 AMGN Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season
        May 1 AMGN CytomX surges on upcoming data for Amgen-partnered cancer drug
        May 1 AMGN Amgen investors await weight-loss drug data
        May 1 AMGN AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
        Apr 30 AMGN Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
        Related Industries: Drug Manufacturers - Major
        Related Stock Lists: Biotechnology Blood Cells Bone Bone Disease Cancer Care Clinic Dialysis Dow Jones Component Drugs Epidermal Growth Factor Receptor Growth Factors Healthcare Providers Hematology Human Therapeutic Products Inflammation Inflammatory Diseases Medicine Metastases Mimics Monoclonal Antibody
        Castration Resistant Prostate Cancer

        Castration-resistant prostate cancer (CRPC) is a type of prostate cancer that is resistant to hormone therapy, which is the primary treatment for prostate cancer. It is also known as hormone-refractory prostate cancer (HRPC). CRPC is an advanced form of prostate cancer that has spread beyond the prostate gland and is no longer responding to hormone therapy. It is usually treated with chemotherapy, radiation therapy, and other treatments.

        Browse All Tags